LabGenomics Past Earnings Performance
Past criteria checks 0/6
LabGenomics's earnings have been declining at an average annual rate of -11.1%, while the Biotechs industry saw earnings growing at 10.8% annually. Revenues have been declining at an average rate of 30.4% per year.
Key information
-11.1%
Earnings growth rate
-10.6%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | -30.4% |
| Return on equity | -8.4% |
| Net Margin | -23.0% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How LabGenomics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 78,360 | -18,038 | 36,056 | 2,747 |
| 31 Dec 23 | 73,127 | -4,674 | 31,590 | 2,812 |
| 30 Sep 23 | 69,848 | 4,135 | 25,553 | 2,390 |
| 30 Jun 23 | 73,188 | 13,558 | 23,389 | 2,290 |
| 31 Mar 23 | 79,804 | 14,483 | 24,715 | 1,807 |
| 31 Dec 22 | 144,773 | 48,397 | 26,170 | 1,865 |
| 30 Sep 22 | 187,009 | 74,151 | 23,500 | 1,398 |
| 30 Jun 22 | 215,952 | 90,800 | 23,080 | 1,289 |
| 31 Mar 22 | 248,011 | 108,702 | 21,284 | 1,490 |
| 31 Dec 21 | 202,407 | 83,855 | 18,484 | 557 |
| 30 Sep 21 | 173,039 | 64,682 | 18,264 | 256 |
| 30 Jun 21 | 146,336 | 49,148 | 16,751 | 0 |
| 31 Mar 21 | 141,632 | 53,802 | 16,334 | 0 |
| 31 Dec 20 | 119,478 | 42,766 | 15,213 | 0 |
| 30 Sep 20 | 97,279 | 38,382 | 13,993 | 0 |
| 30 Jun 20 | 78,956 | 29,479 | 13,079 | 0 |
| 31 Mar 20 | 38,237 | 3,175 | 10,720 | 0 |
| 31 Dec 19 | 33,175 | 962 | 10,699 | 0 |
Quality Earnings: A084650 is currently unprofitable.
Growing Profit Margin: A084650 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A084650 is unprofitable, and losses have increased over the past 5 years at a rate of 11.1% per year.
Accelerating Growth: Unable to compare A084650's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A084650 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (28.8%).
Return on Equity
High ROE: A084650 has a negative Return on Equity (-8.37%), as it is currently unprofitable.